Lacticaseibacillus rhamnosus CECT 8361
Lacticaseibacillus rhamnosus CECT 8361 has a modest research base, with evidence drawn from two randomized controlled trials in which it was used as part of a multi-strain formulation. A 2021 RCT examined high-intensity exercise and antioxidant markers in athletes supplemented with a probiotic product containing this strain, and a 2026 RCT in healthy adults with self-reported anxiety examined mood and perceived stress measures. Because both trials used combination formulations, strain-specific effects cannot be isolated from the available data. Strain-specific human clinical research on CECT 8361 remains limited. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 3 body-system-tagged papers that concern each system. Research coverage, not measured effect.
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 1 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
4 papers reference this strain in the probiotic database.
Discussion
Be the first to comment.
Sign in to join the discussion.